phenylbutyrate
Showing 1 - 25 of 78
Medium-chain Acyl-CoA Dehydrogenase Deficiency Trial in Pittsburgh (Sodium phenylbutyrate)
Recruiting
- Medium-chain Acyl-CoA Dehydrogenase Deficiency
- Sodium phenylbutyrate
-
Pittsburgh, PennsylvaniaUPMC Children's Hospital of Pittsburgh
Oct 4, 2023
Corticobasal Syndrome (CBS) Trial (RAVICTI 1.1 g/ml, Placebo)
Not yet recruiting
- Corticobasal Syndrome (CBS)
- RAVICTI 1.1 g/ml
- Placebo
- (no location specified)
Aug 1, 2023
Hyperammonemia Trial in Belfast (Fezagepras, Sodium phenylbutyrate)
Terminated
- Hyperammonemia
- Fezagepras
- Sodium phenylbutyrate
-
Belfast, Northern Ireland, United KingdomCelerion
Jul 28, 2022
Parkinson's Disease Trial in Aurora (Glycerol Phenylbutyrate)
Completed
- Parkinson's Disease
- Glycerol Phenylbutyrate
-
Aurora, ColoradoUniversity of Colorado Denver Anschutz Medical Center
Apr 15, 2022
STXBP1 Encephalopathy With Epilepsy, SLC6A1 Neurodevelopmental Disorder Trial in Aurora, New York (Glycerol Phenylbutyrate 1100
Active, not recruiting
- STXBP1 Encephalopathy With Epilepsy, SLC6A1 Neurodevelopmental Disorder
- Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]
-
Aurora, Colorado
- +1 more
Jan 24, 2023
Cystic Fibrosis Trial in Denver, Baltimore, Philadelphia (Ravicti low dose, Ravicti high dose, Placebo)
Terminated
- Cystic Fibrosis
- Ravicti low dose
- +2 more
-
Denver, Colorado
- +2 more
Mar 4, 2022
ACHROMATOPSIA 7, Achromatopsia Trial in New York (PBA)
Not yet recruiting
- ACHROMATOPSIA 7
- Achromatopsia
-
New York, New YorkEdward S. Harkness Eye Institute
Apr 4, 2022
Pyruvate Dehydrogenase Complex Deficiency Trial in Napoli (sodium phenylbutyrate)
Completed
- Pyruvate Dehydrogenase Complex Deficiency
- sodium phenylbutyrate
-
Napoli, ItalyFederico II University
Oct 5, 2021
Obese Non Diabetic Trial in Derby (sodium phenylbutyrate)
Recruiting
- Obese Non Diabetic
- sodium phenylbutyrate
-
Derby, Derbyshire, United KingdomUniversity of Nottingham
Aug 25, 2021
Hereditary Diseases, Cholestasis, Intrahepatic Trial (4-Phenylbutyrate)
Not yet recruiting
- Hereditary Diseases
- Cholestasis, Intrahepatic
- (no location specified)
Aug 4, 2022
Monocarboxylate Transporter 8 Deficiency Trial in Rehovot (Glycerol Phenylbutyrate 1100 MG/ML)
Recruiting
- Monocarboxylate Transporter 8 Deficiency
- Glycerol Phenylbutyrate 1100 MG/ML
-
Rehovot, IsraelPediatric Endocrinology Unit, Kapan Medical Center
Aug 22, 2021
Amyotrophic Lateral Sclerosis Trial in Puerto Rico, United States (AMX0035)
Approved for marketing
- Amyotrophic Lateral Sclerosis
-
Los Angeles, California
- +20 more
Oct 14, 2022
Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Neuromuscular Diseases Trial in United States (AMX0035, Placebo)
Completed
- Amyotrophic Lateral Sclerosis
- +7 more
- AMX0035
- Placebo
-
Phoenix, Arizona
- +24 more
Jul 20, 2021
Type 2 Diabetes Trial (4.8 g/m^2/day NaPB, 4.8 g/m^2/day )
Not yet recruiting
- Type 2 Diabetes
- 4.8 g/m^2/day NaPB
- 4.8 g/m^2/day placebo
- (no location specified)
Apr 26, 2023
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases Trial (AMX0035, Placebo)
Not yet recruiting
- Progressive Supranuclear Palsy
- +3 more
- AMX0035
- Placebo
- (no location specified)
Nov 3, 2023
Maple Syrup Urine Disease Trial in Houston (Phenylbutyrate, Placebo powder)
Completed
- Maple Syrup Urine Disease
- Phenylbutyrate
- Placebo powder
-
Houston, TexasBaylor College of Medicine
Mar 6, 2019
Lymphoma, Small Intestine Cancer, Solid Tumor Trial in Baltimore (Azacitidine Injection, sodium phenylbutyrate)
Completed
- Lymphoma
- +2 more
- Azacitidine Injection
- sodium phenylbutyrate
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Jan 9, 2019
Amyotrophic Lateral Sclerosis Trial in Worldwide (Placebo, AMX0035)
Active, not recruiting
- Amyotrophic Lateral Sclerosis
- Placebo
- AMX0035
-
Phoenix, Arizona
- +68 more
Jan 4, 2023
Amyotrophic Lateral Sclerosis Trial in United States (AMX0035)
Enrolling by invitation
- Amyotrophic Lateral Sclerosis
-
San Francisco, California
- +4 more
Jul 20, 2021